glp-1 drugs and fatty liver 8 Benefits of GLP‑1's Beyond Weight Loss GLP-1 Receptor Agonists for Non-Alcoholic

The initial product GLP-1 (137) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (736) amide and GLP-1 (737)

Obesity and Metabolic Syndrome GLP-1 receptor agonists are well-established tools in combating obesity

In 2022, the NHS published data comparing five different providers of the Digital Diabetes Prevention Programme

Along this line, a recent meta-analysis of 11 heterogeneous observational studies primarily consisting of pharmacovigilance and cohort studies reported no significant difference in suicidal outcomes between GLP-1 RAs compared with other anti-hyperglycemic drugs (RR:0.568, 95% Cl:0.077-4.205) [27]

Physiological adaptations to weight loss and factors favouring weight regain

35 Although these CVOTs were not specifically powered to detect differences in HF outcomes, they provided the first valuable signs of the benefit of GLP-1RAs in patients with HF